Galapagos NV (FRA:GXE) EBIT per Share : €-1.92 (TTM As of Mar. 2025)

View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV EBIT per Share?

Galapagos NV's EBIT per Share for the three months ended in Mar. 2025 was €-2.41. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 was €-1.92.

During the past 3 years, the average EBIT per Share Growth Rate was -3.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Galapagos NV's EBIT per Share or its related term are showing as below:

FRA:GXE' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -216.5 Med: -4.8 Max: 28.8
Current: -3

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Galapagos NV was 28.80% per year. The lowest was -216.50% per year. And the median was -4.80% per year.

FRA:GXE's 3-Year EBIT Growth Rate is ranked worse than
63.06% of 1240 companies
in the Biotechnology industry
Industry Median: 8.1 vs FRA:GXE: -3.00

Galapagos NV's EBIT for the three months ended in Mar. 2025 was €-158.7 Mil.

Galapagos NV EBIT per Share Historical Data

The historical data trend for Galapagos NV's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV EBIT per Share Chart

Galapagos NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-4.62

-1.65

-0.94

0.11

-0.03

Galapagos NV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EBIT per Share	Get a 7-Day Free Trial															-0.50	0.92	-2.30	1.88	-2.41

Galapagos NV EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Galapagos NV's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.174	/	65.897
=	-0.03

Galapagos NV's EBIT per Share for the quarter that ended in Mar. 2025 is calculated as

	EBIT per Share		(Q: Mar. 2025 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-158.708	/	65.838
=	-2.41

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.92

Galapagos NV (FRA:GXE) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Galapagos NV EBIT per Share Related Terms

Thank you for viewing the detailed overview of Galapagos NV's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (FRA:GXE) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

GLPGF:USA GLPG:USA GLPG:Netherlands GLPGa:UK 0JXZ:UK GXEA:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Galapagos NV Headlines

No Headlines